Isofol Reports Early Tumor Shrinkage in Patients with Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin
GOTHENBURG, Sweden, January 17, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from…
Privacy & Cookies Policy
These cookies are necessary for the website to function properly. These cookies ensure basic functionalities and security features of the website. These cookies do not store any personally identifiable information.